Clinical Trial Update: Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immunogenicity of the candidate vaccine MVA-MERS-S_DF-1 against Middle East respiratory syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Middle East Respiratory Syndrome

Drugs mentioned

• MVA-MERS-S_DF-1

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: MERS (Middle East Respiratory Syndrome) | Phase 1 | Status: COMPLETED